Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
Status:
Completed
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to
patients with advanced cancer that has spread to the liver. The safety of these drug
combinations will also be studied.